Whether the improvement of hepatic steatosis in these mouse models is a direct outcome of transcriptional regulation by Xbp1 or a secondary consequence of resolved metabolic stress and improved insulin sensitivity remains unclear. This evidence concerns the gene INS and fatty liver disease.